Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block for Perioperative Analgesia in Patients Undergoing Open Splenectomy

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-12-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: purposeblockopioiddoublestatus
  Phrases that lowered it: opensurgerycriteria patientsabdominalhistory
• Sponsor's past termination rate: 0.7% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 272 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 413 (lowers risk) · Sponsor's track record
• Maximum age: 65 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparison of Postoperative Analgesia in Erector Spinae Plane Block (ESPB) v/s Subcostal Transversus Abdominal Plane Block (STAP) in Adults Undergoing Laparoscopic Cholecystectomy. NCT07469410 · started 2025 · scored riskier than 8% of active trials completed
• Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy NCT05369468 · started 2020 · scored riskier than 6% of active trials completed
• Erector Spinae Plane Block NCT04118101 · started 2019 · scored riskier than 12% of active trials completed
• Comparative Study of USG Guided ESPB vs USG Guided PVB For Post-op Analgesia In Patient's After Open Renal Surgeries NCT06728514 · started 2024 · scored riskier than 20% of active trials completed
• Erector Spinae Plane Block in Scoliotic Adolescents NCT03968146 · started 2019 · scored riskier than 15% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.